Credit Suisse’s Alexion Pharmaceuticals ALXN Stock Holding History

Credit Suisse’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,500	Closed	-$811K	–	4344
2019 Q4	$811K	Hold	7,500	–	–	﹤0.01%	3274
2019 Q3	$735K	Hold	7,500	–	–	﹤0.01%	3219
2019 Q2	$982K	Buy	7,500 +900	+14%	+$116K	﹤0.01%	2946
2019 Q1	$892K	Buy	+6,600	New	+$821K	﹤0.01%	2973
2018 Q1	–	Sell	-49,000	Closed	-$5.86M	–	4203
2017 Q4	$5.86M	Buy	+49,000	New	+$5.97M	0.01%	1657
2017 Q3	–	Sell	-50,000	Closed	-$6.08M	–	4292
2017 Q2	$6.08M	Buy	+50,000	New	+$5.82M	0.01%	1507
2013 Q3	–	Sell	-4,000	Closed	-$369K	–	4423
2013 Q2	$369K	Buy	+4,000	New	+$385K	﹤0.01%	3497

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Credit Suisse's ALXN Position: Q3 2021 in Review

Credit Suisse sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,744,843 shares — an estimated $321M sold.

Credit Suisse first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $321M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Credit Suisse reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Credit Suisse sold 1,744,843 Alexion Pharmaceuticals shares in Q3 2021, an estimated $321M.
Credit Suisse first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Credit Suisse's Alexion Pharmaceuticals position peaked at $321M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.